Zalmoxis Eiropas Savienība - horvātu - EMA (European Medicines Agency)

zalmoxis

molmed spa - alogenih t stanica genetski modificirani sa retrovirusni vektor kodiranje za skraćeni oblik ljudske nizak afinitet receptora faktora rasta živaca (Δlngfr) i herpes simplex virus timidin kinaze (hsv-tk mut2) - hematopoietic stem cell transplantation; graft vs host disease - antineoplastična sredstva - zalmoksis je indiciran kao dodatna terapija u haploidentical hematopoetskih matičnih stanica (hsct) odraslih bolesnika s visokog rizika hematoloških malignih bolesti.

Trecondi Eiropas Savienība - horvātu - EMA (European Medicines Agency)

trecondi

medac gesellschaft für klinische spezialpräparate mbh - treosulfan - transplantacija hematopoetskih matičnih stanica - antineoplastična sredstva - treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (allohsct) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.

Phelinun Eiropas Savienība - horvātu - EMA (European Medicines Agency)

phelinun

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastična sredstva - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Horse Allo 20 Eiropas Savienība - horvātu - EMA (European Medicines Agency)

horse allo 20

centauri biotech sl - аллогенная konja masnih мезенхимальных matičnih stanica - konji - za liječenje артроза kod odraslih ne prehrambene proizvode konja.

Thiotepa Riemser Eiropas Savienība - horvātu - EMA (European Medicines Agency)

thiotepa riemser

esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastična sredstva - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Blincyto Eiropas Savienība - horvātu - EMA (European Medicines Agency)

blincyto

amgen europe b.v. - blinatumomab - prekursorska stanica limfoblastične leukemije-limfom - antineoplastična sredstva - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Prevymis Eiropas Savienība - horvātu - EMA (European Medicines Agency)

prevymis

merck sharp & dohme b.v. - letermovir - infekcije citomegalovirusa - antivirusni lijekovi za sustavnu uporabu - prevymis je indiciran za profilaksu citomegalovirus (cmv) reaktivacije i bolesti u odraslih cmv seropozitivne primatelja [r +] transplantacija alogenih krvotvornih matičnih stanica (hsct). treba uzeti u obzir formalne preporuke za odgovarajuće korištenje antivirusnih lijekova.

Arti-Cell Forte Eiropas Savienība - horvātu - EMA (European Medicines Agency)

arti-cell forte

boehringer ingelheim vetmedica gmbh - hrskavičav inducirana periferne krvi konja аллогенных мезенхимальных matičnih stanica - ostali lijekovi za poremećaje mišićno-koštanog sustava - konji - smanjenje od blage do umjerene relaps хромотой povezane s септическим upalom zglobova u konja.

VAXNEUVANCE 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 4mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml Suspenzija za injekciju u napunjenom injekcionom špricu Melnkalne - horvātu - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

vaxneuvance 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 4mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml suspenzija za injekciju u napunjenom injekcionom špricu

druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - pneumokokna polisaharidna konjugovana vakcina, adsorbovana - suspenzija za injekciju u napunjenom injekcionom špricu - 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 4mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml

VAXNEUVANCE 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 4mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml Suspenzija za injekciju u napunjenom injekcionom špricu Melnkalne - horvātu - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

vaxneuvance 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 4mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml suspenzija za injekciju u napunjenom injekcionom špricu

druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - pneumokokna polisaharidna konjugovana vakcina, adsorbovana - suspenzija za injekciju u napunjenom injekcionom špricu - 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 4mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml + 2mcg/0.5ml